Pulmonary effects of timing of antiretroviral therapy initiation

Affiliations

¹ Infectious Diseases, Greys Hospital, Department of Medicine, Pietermaritzburg, KZN, South Africa; Caprisa, University of Kwazulu Natal, South Africa. Electronic address: halimadawood@gmail.com.

Comment

Halima Dawood. Lancet Respir Med. 2016 Dec.

. 2016 Dec;4(12):929-930.

doi: 10.1016/S2213-2600(16)30329-0. Epub 2016 Oct 20.

¹ Infectious Diseases, Greys Hospital, Department of Medicine, Pietermaritzburg, KZN, South Africa; Caprisa, University of Kwazulu Natal, South Africa. Electronic address: halimadawood@gmail.com.

No abstract available

Comment on

Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE; INSIGHT START Pulmonary Substudy Group. Kunisaki KM, et al. Lancet Respir Med. 2016 Dec;4(12):980-989. doi: 10.1016/S2213-2600(16)30319-8. Epub 2016 Oct 20. Lancet Respir Med. 2016. PMID: 27773665 Free PMC article. Clinical Trial.